Publications by authors named "F Cavazzini"

Claim this Profile
N
Nilotinib versus imatinib with early switch from imatinib to nilotinib to obtain treatment-free remission in newly diagnosed chronic myeloid leukemia patients: the analysis of the first co-primary endpoint.
Fausto Castagnetti, Massimo Breccia, Elisabetta Abruzzese, Renato Bassan, Gianni Binotto, Francesco Cavazzini

Leukemia· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Revised "iRR6" model in intermediate-1 risk myelofibrosis patients treated with ruxolitinib.
Francesca Palandri, Filippo Branzanti, Massimiliano Bonifacio, Elena M Elli, Erika Morsia, Francesco Cavazzini

Cancer· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of ELN clinical signs and symptoms on the thrombotic risk in polycythemia vera patients treated with front-line hydroxyurea.
Francesca Palandri, Massimo Breccia, Elena M Elli, Roberto Latagliata, Giulia Benevolo, Francesco Cavazzini

Leukemia· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment strategies and survival after ruxolitinib discontinuation in myelofibrosis patients: The Italian RUX-MF multicenter study.
Francesca Palandri, Massimo Breccia, Erika Morsia, Elena M Elli, Giulia Benevolo, Francesco Cavazzini

Leuk Res· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-World Efficacy Profile of Compassionate Use of Asciminib in an Italian, Multi-Resistant Chronic-Phase Chronic Myeloid Leukemia (CML-CP) Patient Population.
Massimo Breccia, Antonella Russo Rossi, Valentina Giai, Bruno Martino, Carmen Fava, Francesco Cavazzini

Hematol Oncol· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis